×

Faber Report: Biogen Idec Buying Stake in MS Drug

9:42 AM ET Wed, 6 Feb 2013

CNBC's David Faber reports Biogen Idec is buying Elan's stake in MS drug Tysabri for $3.25 billion plus royalties.